A novel protease-activated nanosensor assay effectively identifies pancreatic ductal adenocarcinoma (pdac) in patients with high specificity and sensitivity. The assay achieved 98% specificity and 73% sensitivity for pdac samples and demonstrated an impressive 85% sensitivity for stage I pdac combined with the CA 19-9 biomarker. By leveraging serum protease activity, this rapid and noninvasive method could enhance early detection, improving treatment options and potentially increasing survival rates for patients at risk of developing pdac.
Journal Article by Montoya Mira JL, Quentel A (…) Fischer JM et 12 al. in Sci Transl Med